Utilization of a multispecialty team for the diagnosis of giant cell arteritis reduces patient morbidity

Arash Hassantoufighi1, Rachel LuDo1, Joshpal Dhillion1, Christopher Collins1, Florina Constantinescu1, 2, MedStar Washington Hospital Center, Rheumatology, Washington, United States of America; 2MedStar Washington Hospital Center, Internal Medicine, Washington, United States of America

Background: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most commonly seen in older adults with a peak incidence in the seventh decade of life. A diagnosis of GCA is often considered in any patient over the age of 50 years who complains of or is found to have new onset headache, acute visual disturbances, jaw claudication, unexplained fever, or elevated inflammatory markers. Because the manifestations of GCA can vary considerably from patient to patient, often with transient and fluctuating symptoms, an accurate diagnosis can be challenging. Even in the setting of a negative temporal artery biopsy, many patients are treated empirically based on the perceived probability of disease. This approach can lead to significant morbidity from prolonged medication exposure and unnecessary procedures.

Objectives: The aim for this project was to look at the impact of a collaborative effort amongst three specialties, rheumatology neurology and ophthalmology, which composed a consultation based “GCA team”, the goal of which was to improve how GCA is diagnosed and subsequently managed.

Methods: We conducted a retrospective study of all patients suspected to have GCA at our institution over the last 2.5 years that had either been seen by the GCA team or not. The GCA team met either in person or had a conference call to discuss each case and make a joint decision regarding the diagnosis and treatment. Data extracted included patient demographics, symptoms on presentation, labs, biopsy results and cumulative prednisone dose.

Results: A total of 30 patients (19 female, 11 male) were evaluated; 19 were seen by the GCA team and 11 were not. The mean ages of the patients in each group were the similar (GCA Team 70.6 (SD 12.5) vs no GCA Team 70.3 (SD 12.3)). The mean ESR between the two groups was also similar (GCA Team 53.3 (SD 30.2) vs no GCA Team 53.8 (SD 27.2)).

Conclusion: This approach to diagnosing GCA which can serve as a model for other healthcare systems can avoid as well as limiting unnecessary prednisone exposure.

Disclosure of Interests: None declared

AB0062

Clinical usefulness of lung ultrasound in active granulomatosis with polyangiitis with lung involvement – preliminary data

Anna Mesjak, Natalia Buda, Zbigniew Zdrojewski, Medical University of Gdańsk, Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Gdańsk, Poland

Background: Lung involvement is observed in 43% to 94% of patients with granulomatosis with polyangiitis (GPA) (1). In about 10% of cases, the lung is the only organ involved and in as many as 20% of patients without clinical symptoms of lower respiratory tract involvement, abnormalities in chest imaging examinations can be found (2). The efficacy of lung ultrasound (LUS) is very well documented in many pulmonary diseases (3,4). Single publications indicate its applicability also in diagnostics of complications secondary to systemic connective tissue disease, e.g., lung fibrosis or diffuse alveolar hemorrhage (5,6). The necessity of repeating chest imaging examinations increases the patient’s exposure to ionizing radiation. Thus, the possibility of limiting such exposure through the application of LUS as the diagnostic modality appears extremely inviting.

Objectives: The aim of this study was to assess lesions detected by ultrasound in patients with active granulomatosis with polyangiitis (GPA) in comparison to abnormalities found by computed tomography (CT).

Methods: We analyzed the clinical and radiological data of 12 patients (5 women/7 men, mean age 47.9 years/range 18-80) with active PR3-ANCA-associated vasculitis with lung involvement (Birmingham Vasculitis Activity Score, BVASv3 mean 5.7/range 1-12). LUS was performed in the sitting and lying positions, using the convex (26 MHz) and linear (4-12 MHz) transducers placed to each intercostal space over the chest wall (anterior, lateral and inferior). Chest CT was performed according to a standard protocol with the use of a 64-slice CT scanner made by GE. The images obtained in LUS were compared to changes detected in CT scans. The study protocol was approved by an independent local Bioethics Committee (NKKBN/474/2018).

Results: In all patients with lung infiltrations, changes were visible in the LUS, but the visualized infiltrates and caves include only these lesions that were adjacent to the line of pleura. LUS revealed infiltrates as well as infiltrates with features of disintegration and cavities. Subpleural infiltrates in ultrasound were visualized as hypoechoic round or oval consolidations, without central flow visible in color Doppler (CD) and power Doppler (PD) modes. Caves visualized in LUS were round and anechoic; flow in CD and PD modalities was also absent. In some cases, we observed hypoechoic round or oval infiltrates with features of disintegration, partly filled in with fluid content (anechoic).

Conclusion: Due to the harmlessness of ultrasonography, LUS can be repeatedly performed. In addition, ultrasound examination can be performed during hospitalization at the patient’s bedside as well as during a visit to the rheumatologist’s office.

Disclosure of Interests: None declared


References


Disclosure of Interests: None declared


AB0063

Scotland’s first fast track temporal artery ultrasound referral pathway for suspected giant cell arteritis

John McLaren, Jane Gibson, Sarah Hallwood. NHS Fife, Fife Rheumatic Diseases Unit, Kirkcaldy, United Kingdom

Background: Giant cell arteritis (GCA) is associated with loss of vision (LOV). Rapid referral for specialist assessment including temporal artery ultrasound (TAU) reduces the risk of LOV and the need for temporal artery biopsy (TAB). Two
Consultant Rheumatologists (JSM & JHG), formally trained in TAU, established Scotland’s First Fast Track Referral Pathway for Suspected GCA using TAU on 21.03.17. A third Consultant (SLJ), whose formal Vascular ultrasound training occurred later, joined the Service on 10.04.18. We present here our Outcome data and also our experience of this new Service for NHS Fife, the first of it’s kind in Scotland.

Methods: We prospectively recorded data on all referrals to our Fast Track Service for patients with suspected GCA from 21.03.17 onwards. High risk Aneurysms; a population of 370,000; and constitutes 6.8% of the Scottish Population (5,425,000).

Results: Up until 20.11.17 (20 months) we received a total of 142 referrals, representing an average of 7 per month, or around 2 per week. 54 (38%) were deemed to have a very low probability of GCA based on their age, history & CRP and were not seen or scanned. 88 (62%) of referrals underwent Fast Track assessment including TAU (62 F; 26 M); Mean age 71 (range 52-88). Time from referral to assessment was as follows : (25) 28% were seen on the same day; (60) 68% were seen by the next day; (69) 78% were seen within 2 days of referral; (84) 95% were seen within 3 days of referral. 25/88 (28%) patients were diagnosed with GCA. Of these, 14 patients had a positive TAU and did not require TAB, 9 patients had an equivocal or negative TAU and were diagnosed on TAB. Only 1/25 GCA patients experienced LOV (4%). The patient was an 82 year old male diabetic who presented to Ophthalmology with unilateral LOV but no symptoms of GCA and also with a normal CRP (4.1mg/L). However, he had stopped 1mg of prednisolone for PMR 2 weeks prior to developing LOV. TAU was positive, but in view of the silent GCA, intracranial hypertension, and 3 had dural sinus thrombosis. Articular involvement was recorded in 79 (59.8%) patients (it was observed 25 monoarthritis, 24 oligoarthritis, 6 polyarthritis and 58 patients had arthropal- gia). Vascular involvement was present in 43 (32.6%) cases: deep venous thrombosis in 33 patients (11% in locations other than the extremities); pulmonary embolism in 7; 21 thrombophlebitis; and 6 patients aneurysms (only 2 pulmonary arterial aneurysms). Digestive involvement was present in 12 (9.1%) patients, with predominant colon involvement (8 cases).

The most prescribed drugs were corticosteroids (85.6%) and colchicine (77.3%), followed by azathioprine (36.4%) and cyclosporine A (33.5%). Other prescribed drugs were thalidomide (6.1%), chlorambucil (9.3%), methotrexate (4.5%), anti-TNF-alpha therapies (infliximab 6.8% and adali- mumab 2.3%), cyclophosphamide (3%), mycophenolate (3.8%), leflunomide (1.5%) and 22% received antiacoagulation.

Conclusion: Clinical features of our patients are similar to those of other European cohorts, although a high prevalence of organic involvement (ocular, neurological, vascular and joint) should be highlighted.

REFERENCES

Disclosure of Interests: None declared

AB0605

SERUM NEOPTERIN AND ISCHEMIA MODIFIED ALBUMIN LEVELS ARE ASSOCIATED WITH THE DISEASE ACTIVITY OF ADULT IMMUNOGLLOBULIN A VASULITIS (HENOCHE–SCHONLEIN PURPURA)

Annette Omme1, Seda Colak2, Sevinc Can Sandıkçı1, Cigdem Yuce1, Abdulsamet Erden3, Erdim Sertoglu4, Taner Özgürta5
1Health Sciences University, Ankara Numune Training and Research Hospital, Rheumatology, Ankara, Turkey; 2Health Sciences University, Ankara Numune Training and Research Hospital, Clinical Biochemistry, Ankara, Turkey; 3Yildirim Beyazit University, Rheumatology, Ankara, Turkey; 4University of Health Sciences, Gülhane School of Medicine, Medical Biochemistry, Ankara, Turkey

Background: Immunoglobulin A vasculitis (IgAV) [formerly known as Henoch–Schönlein purpura (HSP)] is an antigen mediated systemic vasculitis which primarily affects skin, gastrointestinal system and small vessels of kidney. Exact pathogenesis of IgAV remains unknown. A few clinical studies have identified serum neo-pterin levels, hsCRP and IMA as potential markers of diagnosis and disease activity.

Methods: Thirty-four consecutive adult patients (24 males and 10 females) admitted to the rheumatology clinic of Ankara Numune Training and Research Hospital meeting the IgAVAmerican College of Rheumatology (ACR) criteria were enrolled in this cross-sectional study. Demographic and clinical features of IgAV and control group were recorded into a pre-defined protocol. Disease activity was categorized as “remission” or “active” according to BVAS. BVAS ≥1 was accepted “active”.Serum neopterin levels, hsCRP and IMA were evaluated according to BVAS and compared to healthy control group.

Results: Serum median (IQR) neo-pterin, IMA levels and hsCRP were higher in the study group than in controls [2.01 (12.5) ng/mL vs. 1.77 (1.37) ng/mL, 0.67 (0.2) ng/mL vs. 0.43 (0.17) ng/mL, 5.6 (17.1) mg/L vs. 1.55 (1.6) mg/L, p=0.095, p=0.001 and p=0.002, respectively]. When evaluated according to BVAS, IMA and hsCRP levels were significantly higher in the group with active disease [0.77 (0.12) vs. 0.61 (0.13) and 14.85 (4.6) vs. p=0.009 and p=0.03, respectively]. Serum neo-pterin levels were sig- significantly higher in the active group compared to BVAS [18.95 (32.38) vs. 1.63 (1.48), p<0.001].

Conclusion: Oxidative stress is important in HSP pathogenesis. Roles of hsCRP, Neopterin and IMA as potential markers of diagnosis and disease activity seem to be worth studying in the future studies with larger study groups.

Disclosure of Interests: None declared

AB0604

CLINICAL FEATURES AND TREATMENT IN A COHORT OF PATIENTS WITH BEHÇET DISEASE IN A TERTIARY HOSPITAL OF BARCELONA

Joan Maria Mercedes Torras, Alfredo Guillén-Dei-Castillo, Segundo Bujan Rivas, Jaume Mestre Torres, Roser Solans-Laquè. Barcelona, Barcelona, Spain

Background: Behçet disease (BD) is considered a systemic vasculitis according to the Chapel-Hill classification, which occurs most frequently between latitudes 30 and 45 north and in the area of the Old Silk Route. Turkey has the highest prevalence, followed by Japan. In Spain, a prevalence of 7.5 cases per 100000 persons has been estimated. The epidemiological and clinical characteristics of European patients with BD vary with respect to those of the Turkish and Japanese cohorts.

Objectives: Description of clinical features and treatment received in a cohort of patients diagnosed with BD in an Internal Medicine Unit of a tertiary centre from Barcelona.

Methods: Retrospective, observational study. Epidemiological, clinical and laboratory data were obtained from clinical charts. SSPS package was used to perform statistical analysis.

Results: 132 patients (56.6% men) diagnosed over the last 30 years and followed-up until the censoring data were included. 112 (84.8%) were Caucasians, 15 (11.4%) from North Africa, 4 (3%) Asian and 1 (0.8%) from South America. 2 (1.5%) patients had a family history of BD and 9 patients (6.8%) a family history of other rheumatic diseases. 43.9% (58 patients) were HLA-B27 positive. Oral or genital ulcers were present in 131 (99.2%) patients and skin involvement in 106 (80%) cases. 44.6% had erythema nodosum, 59% had acne-like lesions and 9% had cutaneous vasculitis. Ocular involvement was observed in 69 cases (52.3%): 27 patients unilateral and 8 bilateral anterior uveitis; 14 unilateral and 3 bilateral posterior uveitis; 10 patients unilateral and 14 bilateral panuveitis; 19 unilateral retinal vasculitis and 12 bilateral. Neurological involvement was present in 37 (28%) patients: 10 parenchymal disease and 17 cases non-parenchymal disease (aseptic meningitis or vasculitis); 8 patients benign intracranial hypertension, and 3 had dural sinus thrombosis. Articular involvement was recorded in 79 (59.8%) patients (it was observed 25 monoarthritis, 24 oligoarthritis, 6 polyarthritis and 58 patients had arthropal- gia). Vascular involvement was present in 43 (32.6%) cases: deep venous thrombosis in 33 patients (11% in locations other than the extremities); pulmonary embolism in 7; 21 thrombophlebitis; and 6 patients aneurysms (only 2 pulmonary arterial aneurysms). Digestive involvement was present in 12 (9.1%) patients, with predominant colon involvement (8 cases).

The most prescribed drugs were corticosteroids (85.6%) and colchicine (77.3%), followed by azathioprine (36.4%) and cyclosporine A (33.5%). Other prescribed drugs were thalidomide (6.1%), chlorambucil (9.3%), methotrexate (4.5%), anti-TNF-alpha therapies (infliximab 6.8% and adali- mumab 2.3%), cyclophosphamide (3%), mycophenolate (3.8%), leflunomide (1.5%) and 22% received antiacoagulation.

Conclusion: Clinical features of our patients are similar to those of other European cohorts, although a high prevalence of organic involvement (ocular, neurological, vascular and joint) should be highlighted.